Orthogon Therapeutics Raises $4.4 Million in Series A Financing

CANTON, Mass., March 8, 2018 /PRNewswire-iReach/ — Orthogon Therapeutics, LLC, a drug design company developing a pipeline of preclinical assets, announced today the closing of a $4.4 million Series A financing. The investment round was co-led by Over-the-Rhine Ventures of Cincinnati, Ohio as well as Holbrook Angels of Boston, Massachusetts. The new funding will be used to advance the discovery of a portfolio of high-value lead drug candidates including nomination of the Company’s first pre-clinical candidate for the treatment of viral infections in organ transplant recipients.

‘We are very pleased to have attracted a strong group of investors who recognize the potential of the Orthogon technology platform in adding value to the early stages of drug development,’ said Ali Munawar, CEO of Orthogon. Mr. Munawar was previously the founding CEO of Novira Therapeutics, Inc., acquired by Johnson & Johnson in 2015.

In conjunction with the financing, Dr. P. A. Mehta, will join the Orthogon Board of Directors. ‘Orthogon is a transformative drug discovery engine,’ said Dr. Mehta, Managing Partner of Over-the-Rhine Ventures. Dr. Mehta went on to state the following, ‘We are excited to support experienced life sciences entrepreneurs who are motivated by a desire to improve the lives of patients.”

About Orthogon Therapeutics, LLC

Orthogon Therapeutics is a pre-clinical stage, drug design company that leverages a constellation of innovative technologies to discover and develop small molecules that modulate challenging but sought-after drug targets. The Company mission is to efficiently produce high-quality, medicinal, lead molecules that can be developed in a partnership model.

For additional information about Orthogon Therapeutics, please visit www.orthogontherapeutics.com.

Contact: Ali H. Munawar
Title: Chief Executive Officer & Founder
Company: Orthogon Therapeutics, LLC
Phone: 1-339-502-9108
Email: info@orthogontherapeutics.com

Media Contact: Ali Munawar, Orthogon Therapeutics, LLC, 339-502-9108, amunawar@orthogontherapeutics.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Orthogon Therapeutics, LLC